Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to six newly hired non-executive employees on August 1, 2026. The independent Compensation Committee approved these grants as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
The awards comprise stock options to purchase an aggregate of 451,000 ordinary shares, with a 10-year term and an exercise price of $28.99 per share. Each option vests 25% on the first anniversary of the employee’s start date and then in equal monthly installments over the following 36 months. The options are granted under the 2022 Damora Therapeutics Inducement Plan and are subject to the plan and related option award agreements.
Loading...
Loading translation...
Positive
Inducement options for new hires covering 451,000 shares
Long-term incentives with 10-year option term and four-year vesting
Negative
Potential shareholder dilution from options on 451,000 shares
Exercise price fixed at $28.99, limiting flexibility if share price falls
News Explained
The August 1 grants are options rather than an immediate share issuance: they create a potential future issuance of 451,000 ordinary shares to six new employees, subject to the stated vesting schedule.
Market Context
DMRA’s prior inducement-grant events showed 10.67% and -0.12% 24-hour reactions, while the current a...
Analysis
DMRA’s prior inducement-grant events showed 10.67% and -0.12% 24-hour reactions, while the current award covers six hires. Recent net selling and low short positioning add risk context without resolving the grant’s effect.
Key Figures
New hires:six employeesGrant date:August 1, 2026Options granted:451,000 ordinary shares+4 more
7 metrics
New hiressix employeesInducement grants announced August 3, 2026
Grant dateAugust 1, 2026Date equity awards were granted
"The inducement grants were approved by Damora’s independent Compensation Committee"
Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.
Nasdaq Listing Rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"with a 10-year term and an exercise price of $28.99 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on August 1, 2026.The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of options to purchase an aggregate of 451,000 Damora ordinary shares with a 10-year term and an exercise price of $28.99 per share.All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of an option award agreement.
About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.
What equity inducement grants did Damora Therapeutics (DMRA) announce on August 3, 2026?
Damora Therapeutics announced stock option inducement grants covering 451,000 ordinary shares for six newly hired non-executive employees. According to Damora, the options have a 10-year term, with vesting over four years under its 2022 Inducement Plan.
What is the exercise price and term of the new Damora Therapeutics (DMRA) inducement stock options?
The inducement options have an exercise price of $28.99 per share and a 10-year term. According to Damora, the options were granted on August 1, 2026, as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
How do the Damora Therapeutics (DMRA) inducement options vest for the six new employees?
The inducement options vest 25% on the first anniversary of each employee’s start date, then monthly for 36 months. According to Damora, this structure results in full vesting over approximately four years, aligning employees’ incentives with longer-term company performance.
Under which plan were the Damora Therapeutics (DMRA) August 2026 inducement grants issued?
The inducement grants were issued under the 2022 Damora Therapeutics Inducement Plan. According to Damora, the options are also subject to the terms and conditions of an option award agreement governing each recipient’s specific grant.
Why did Damora Therapeutics (DMRA) use Nasdaq Listing Rule 5635(c)(4) for these inducement grants?
Damora used Nasdaq Listing Rule 5635(c)(4) to grant options as material inducements to employment for six new hires. According to Damora, this rule allows equity awards to new employees without prior shareholder approval when used as hiring incentives.
How many employees received Damora Therapeutics (DMRA) inducement option grants in August 2026?
Six newly hired non-executive employees received the inducement option grants. According to Damora, these employees were granted options to purchase an aggregate of 451,000 ordinary shares, subject to the company’s 2022 Inducement Plan and option award agreements.
